Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge J Castillo

Showing results (281-290 of 343) with videos related to

Pageof 35
Sort By:
Haematologica|March 31, 2018
<i>MYD88</i> mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in <i>CXCR4</i>Maria Luisa Guerrera, Nickolas Tsakmaklis, Lian Xu, et al.
Journal of Geriatric Oncology|November 30, 2024
Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL)Myrna Candelaria, Luis Villela, Luis F Oñate-Ocana, et al.
American Journal of Hematology|March 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström MacroglobulinemiaJorge J Castillo, Andrew R Branagan, Alberto Guijosa, et al.
Haematologica|October 21, 2016
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndromeMonique C Minnema, Eva Kimby, Shirley D'Sa, et al.
Blood|March 3, 2018
BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanismJiaji G Chen, Xia Liu, Manit Munshi, et al.
Cancer|September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective studyJorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
Seminars in Hematology|May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitorsJorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
British Journal of Haematology|November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinibJorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
British Journal of Haematology|September 30, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control studyArtur Jurczyszyn, Hareth Nahi, Irit Avivi, et al.
Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Pageof 35

Showing results (281-290 of 343) with videos related to

Sort By:
Pageof 35
Haematologica|March 31, 2018
<i>MYD88</i> mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in <i>CXCR4</i>Maria Luisa Guerrera, Nickolas Tsakmaklis, Lian Xu, et al.
Journal of Geriatric Oncology|November 30, 2024
Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL)Myrna Candelaria, Luis Villela, Luis F Oñate-Ocana, et al.
American Journal of Hematology|March 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström MacroglobulinemiaJorge J Castillo, Andrew R Branagan, Alberto Guijosa, et al.
Haematologica|October 21, 2016
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndromeMonique C Minnema, Eva Kimby, Shirley D'Sa, et al.
Blood|March 3, 2018
BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanismJiaji G Chen, Xia Liu, Manit Munshi, et al.
Cancer|September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective studyJorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
Seminars in Hematology|May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitorsJorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
British Journal of Haematology|November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinibJorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
British Journal of Haematology|September 30, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control studyArtur Jurczyszyn, Hareth Nahi, Irit Avivi, et al.
Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Pageof 35